Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - rasburicase - injection, powder, for solution - 1.5 mg/vial - rasburicase 1.5 mg/vial

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - rasburicase - hyperuricemia - all other therapeutic products - treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.

Canada - English - Health Canada

sanofi-aventis canada inc - rasburicase - powder for solution - 1.5mg - rasburicase 1.5mg - enzymes

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - rasburicase - powder and solvent for solution for infusion - 1.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - rasburicase - powder and solvent for solution for infusion - 7.5mg

Canada - English - Health Canada

sanofi-aventis canada inc - rasburicase - powder for solution - 7.5mg - rasburicase 7.5mg - enzymes

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis france, france - rasburicase - powder and solvent for solution for infusion - 7.5 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi aventis france, france - rasburicase - powder and solvent for solution for infusion - 1.5 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - rasburicase 1.5mg - powder for infusion - 1.5 mg - active: rasburicase 1.5mg excipient: alanine dibasic sodium phosphate dihydrate dibasic sodium phosphate dodecahydrate mannitol monobasic sodium phosphate dihydrate poloxamer 188 water for injection - the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rasburicase 7.5mg - powder for infusion - 7.5 mg - active: rasburicase 7.5mg excipient: alanine dibasic sodium phosphate dihydrate dibasic sodium phosphate dodecahydrate mannitol monobasic sodium phosphate poloxamer 188 water for injection - the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.